Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

COMy Virtual 2020

Highlights

View all
1:59
Myeloma: BiTEs & CARs
Shaji Kumar • 12 May 2020
8:13
Proteasome inhibitors: key drugs in multiple myeloma
Maria-Victoria Mateos • 14 May 2020
9:25
MGUS diagnosis: a step-by-step approach
Graham Jackson • 16 May 2020
11:27
Jesús San Miguel: Is myeloma curable?
Jesús San Miguel • 13 May 2020

Myeloma in the COVID-19 era

View all
2:28
The impact of COVID-19 on clinical practice
Irene Ghobrial • 28 Apr 2020
5:09
Addressing the imbalances & disparities amid COVID-19
Kenneth Anderson • 4 May 2020
2:10
Myeloma & COVID-19: minimizing risk while maximising treatment
Shaji Kumar • 11 May 2020
2:56
Novel drugs for myeloma thromboprophylaxis
Heinz Ludwig • 13 May 2020

MRD Updates

View all
1:37
MRD in myeloma
Keith Stewart • 30 Apr 2020
1:46
MRD: the most relevant prognostic factor in myeloma
Bruno Paiva • 15 May 2020
6:33
MRD as a tool to discontinue therapy in MM?
Luciano Costa • 11 May 2020
5:06
Amyloidosis treatment & response determination
Shaji Kumar • 11 May 2020

Transplant Updates

View all
1:36
Bortezomib and dexamethasone after ASCT for high-risk MM
Elena Zamagni • 6 May 2020
5:52
Transplant for all eligible MM patients?
Arnon Nagler • 15 May 2020
5:18
Upfront treatment in transplant candidates
Jesús San Miguel • 12 May 2020
3:19
Updates on multiple myeloma management
Elena Zamagni • 6 May 2020

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals